subscribe: Posts | Comments

Postpartum haemorrhage drug under WHO spotlight

0 comments

Summary of story from IRIN 16.03.11

A drug that many health experts say can drastically cut postpartum haemorrhage (PPH) – the leading cause of maternal deaths in the developing world – will be in the spotlight this month during the World Health Organization’s (WHO) biennial review of its model list of essential medicines.

Health groups are urging WHO to include misoprostol for the prevention and management of PPH, or excessive bleeding following childbirth.

WHO denied misoprostol for prevention of PPH in 2009 but proponents hope new evidence presented for the 21-25 March WHO meeting in the Ghanaian capital of Accra will bring a change of mind.

Experts say that one advantage of misoprostol for treating PPH in developing countries is that it is stable at room temperature and can be administered in tablet form.

The primary drugs for PPH – oxytocin and ergometrine – need refrigeration and are injected. While oxytocin is cheaper, misoprostol is more cost-effective in many settings because of these other features.

Such drugs – called oxytocics – cause the uterus to contract, speed up delivery of the placenta and lessen blood loss.

“It is simply pragmatic – I am 100 percent in support of including misoprostol among our means for preventing or treating PPH until we get a better option,” Lawal Oyeneyin, chief medical director at Mother and Child Hospital, Akure, Ondo State, Nigeria, told IRIN. He is among several who submitted letters of support.

PPH causes about a quarter of maternal deaths worldwide, according to WHO. Oyeneyin said it is “without a doubt” the most common cause of maternal death in Ondo State. “Why exclude misoprostol when the benefits outweigh the risks?”

Médecins Sans Frontières also wrote in support of the drug. “Oral misoprostol is a useful alternative for injectable oxytocics when they are not available or ineffective,” said MSF international medical coordinator Myriam Henkens.

The essential medicines list is a guide for national and institutional essential medicines, according to WHO. While governments are not bound to follow it, the model list heavily influences national health ministries, experts say.

Leave a Reply

Your email address will not be published. Required fields are marked *